Anti-CTLA-8 / IL-17a Reference Antibody (netakimab) is a monoclonal antibody used as a reference standard in research and diagnostic assays. It targets interleukin-17A (IL-17A), a key cytokine in inflammatory pathways. Netakimab, the therapeutic counterpart, is used in the treatment of moderate to severe plaque psoriasis by neutralizing IL-17A, reducing skin inflammation, decreasing keratinocyte hyperproliferation, and alleviating symptoms such as scaling, redness, and plaque formation. It is also under investigation for other autoimmune conditions like psoriatic arthritis and ankylosing spondylitis. Administered via subcutaneous injection in clinical settings, it provides a targeted biologic therapy for patients unresponsive to conventional treatments like methotrexate or phototherapy.